Your SlideShare is downloading. ×
ResearchMoz.us: Seasonal Influenza Vaccine Market in Asia-Pacific to 2018
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

ResearchMoz.us: Seasonal Influenza Vaccine Market in Asia-Pacific to 2018

486

Published on

seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market …

seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
486
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Asia-Pacific Seasonal Influenza Vaccine Market to 2018: Positive Impactof Government Support Offset by Limited Production Capacity, HighInvestment and Strict Regulations as Barriers to New EntrantsSeasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of GovernmentSupport Offset by Limited Production Capacity, High Investment and Strict Regulations asBarriers to New Entrants which essentially provides insights into the seasonal influenzavaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deepinto vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, thegeographical distribution of seasonal influenza vaccines across Japan, Australia, NewZealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are alsoprovided in the report.The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. Thereport also reveals the seasonal influenza vaccine R&D pipeline and offers profiles ofpromising vaccines. The report explores the competitive landscape including profiles for topcompanies. Finally, the key trend analysis on mergers and acquisitions, and licensingagreements involving seasonal influenza vaccines is also presented. Treatment of seasonalinfluenza is dominated by two categories of treatment options, vaccines and antiviraltherapies. In the recent years it was observed that demand for seasonal influenza vaccineshave increased due to changed perception of patient population. The patient population is ofthe opinion that preventive healthcare is better compared to curative healthcare; this led toincreased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is anattractive market for seasonal influenza vaccine manufacturers. Major drivers in the marketis increasing awareness, increasing vaccination coverage in the APAC countries and risinggovernment support for immunization against seasonal influenza. Major restraints of themarket are variable demand and limited production capacity. Traditional egg basedmanufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines.View Full Report With TOC: http://www.researchmoz.us/seasonal-influenza-vaccine-market-in-asia-pacific-to-2018-positive-impact-of-government-support-offset-by-limited-production-capacity-high-investment-and-strict-regulations-as-barriers-to-new-entrants-report.htmlCell culture based production of vaccines is expected to reduce the problems associated withthe production and use of seasonal influenza vaccines which will further increase thevaccination coverage in the APAC region. GBI Research Analysis shows that the seasonalinfluenza vaccine market in the APAC Region is a fast growing market. This is due toincreased vaccination coverage against seasonal influenza in the region. GBI Researchforecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of
  • 2. 9% during the period 2011–2018 from $1,015m in 2011 to $1,879m by 2018. This growthis driven by factors such as increasing awareness on influenza caused by threat of pandemicinfluenza, increasing vaccination coverage because of the governments’ support, growingpopulation in the APAC region and entry of novel vaccines and production technologies. GBIResearch finds that the Philippines’ seasonal influenza vaccine market is the most attractivein the seasonal influenza vaccine market for Asia-Pacific region both in terms of value andgrowth rate. Other attractive markets in terms of growth rate are Malaysia’s andSingapore’s seasonal influenza vaccine markets.Australia’s seasonal influenza vaccine market is also a large sized attractive market forecastto grow at a healthy growth rate during the period 2011–2018. In-depth analysis of thereport is based on propriety databases, primary and secondary research and in houseanalysis by the GBI Research team of experts. GBI Research analysis shows that the R&Dpipeline for the seasonal influenza vaccines is moderately strong with approximately 50% ofthe pipeline in the Phase II and Phase III. The major vaccine manufacturers are focusedupon acquiring new technologies and strengthening their presence in the market bycollaborating with or acquiring small and medium sized biotech companies that have strongvaccine candidates in their pipeline. The R&D activity also indicates development of newtechnologies and novel vaccines that can revolutionize the market in near future.ScopeThe report analyses vaccination patterns, market characterization, regulatory landscape,pipeline analysis, competitive landscape and key M&A trends in the seasonal influenzavaccine market in the APAC region.The report coversData and analysis on the seasonal influenza vaccine market in the Asia-Pacific Regionincluding Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong,India and Singapore.Market forecasts for the seasonal influenza vaccines from 2011 to 2018Market Data on geographical landscape including country wise vaccination coverage, publicand private contribution on total doses, price of vaccine, market size and market share.Key drivers and restraints that have created significant impact on the market. http://www.researchmoz.us/seasonal-influenza-vaccine-market-in- asia-pacific-to-2018-positive-impact-of-government-support-offset- by-limited-production-capacity-high-investment-and-strict- regulations-as-barriers-to-new-entrants-report.htmlRegulatory landscape including the pharmaceutical product approval process and overviewof regulatory authorities in the countries in Asia-Pacific regionCompetitive landscape of the seasonal influenza vaccine market in Asia-Pacific regionincluding top companies profiles. The key companies studied in this report are SanofiPasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSLBiotherapies and Crucell.
  • 3. Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 inthe seasonal influenza vaccine market.Reasons to BuyThe report will aid business development and marketing executives strategizingtheir product launches:Build effective strategies to launch their pipeline products by identifying potentialgeographies.Exploit in-licensing and out-licensing opportunities by identifying products that mightprobably fill their portfolio gaps.Develop key strategic initiatives by studying the key strategies of top competitors.Develop market-entry and market expansion strategies by identifying the geographicmarkets poised for strong growth.Reinforce R&D pipelines by identifying new target mechanisms which can produce first inclass vaccines with more efficacy and better safety.Buy a copy of this report:http://www.researchmoz.us/sample/checkout.php?rep_id=165775&type=SRelated Reports:1. Adult and Adolescent Vaccines Market to 2018Adult and Adolescent Vaccines Market to 2018. The report provides insights into thevaccines in the adult and adolescent vaccines market, including market forecasts up to2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market,as well as insights into the adult and adolescent vaccines market’s Research andDevelopment (R&D) pipeline. The report provides in-depth analysis of the unmet needs,drivers and barriers that affect the global adult and adolescent vaccines market. The reportanalyzes the market for adult and adolescent vaccines in the US, and the top five countriesin Europe (the UK, Germany, France, Italy and Spain) and Japan.The report discusses the global pipeline for adult and adolescent vaccines across variousstages of development. The report is built using data and information sourced fromproprietary databases, primary and secondary research and in-house analysis by GBIResearch’s team of industry experts. GBI Research found that the adult and adolescentvaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at aCompound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. Themarket is projected to witness a growth of 5.6% during the 2011–2018 forecast period toreach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by
  • 4. increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for usein people aged 50 and older. The pneumococcal vaccines market is expected to grow at aCAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in2011.2. X-ray Systems Market to 2019X-ray Systems Market to 2019 – Enhanced Imaging Capability, Better ProceduralEfficiency and Portability to Drive Future Growth of Digital X-ray Systems looks atthe market, competitive landscape, and trends for the three X-ray systems marketsegments: digital X-ray systems, analog X-ray systems and retrofit X-ray systems.The report provides comprehensive information on the key trends affecting thesesegments, and key analytical content on the market dynamics. The report alsoreviews the competitive landscape and gives a detailed analysis of each segment’spipeline products, as well as details of important M&A deals. It is built using dataand information sourced from proprietary databases, primary and secondaryresearch and in-house analysis by GBI Research’s team of industry experts.3. Oncology Therapeutics Market in India to 2018Oncology Therapeutics Market in India to 2018 - Introduction of Market-BasedPricing to Fuel Price Wars and Intense Competition Among Domestic andMultinational Players’, which provides in-depth analysis of the key therapeuticindications of oncology, breast cancer, colorectal cancer, prostate cancer, lungcancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It alsolooks at treatment usage patterns and includes insights into the oncology R&Dpipeline. The Indian oncology therapeutics market for breast cancer, lung cancer,colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011.The slower growth in the forecast period is mainly due to the reduction in theprice of leading marketed products for breast cancer, colorectal cancer, lungcancer and NHL after all 348 drugs on the National List of Essential Medicines(NLEM) are brought under price control regulations. The limitations of the currentmarket are unclear patent laws, restrictive pricing and reimbursement policies,ailing infrastructure, and insufficient government aid. Low patient affordability isalso a major restraint, and one that reimbursement and insurance policies mustaddress if the market is to develop in the future.For More Information Kindly Contact:Mrs.Sheela AK
  • 5. Tel:+1-518-618-1030Email: sales@researchmoz.us

×